TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6157338

Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (azatadine maleate and pseudoephedrine sulfate)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Single components (azatadine maleate or pseudoephedrine sulfate)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31863339

Group type: EXPERIMENTAL
Intervention: Peer presence (two same-sex peers)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Alone (no peer presence)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Performance on the stoplight game
Number of subjects: 327
Study: 30685679

Group type: EXPERIMENTAL
Intervention: SurVeil drug-coated balloon (DCB)
Number of subjects: 446

Group type: COMPARATOR
Intervention: IN.PACT Admiral drug-coated balloon (DCB)
Number of subjects: 446
Study: 28744898

Group type: EXPERIMENTAL
Intervention: Chewing gum with three different degrees of softness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compressing extremely soft gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting
Number of subjects: 20
Study: 26614406

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25149549

Group type: EXPERIMENTAL
Intervention: MUM1 positivity (cutoff value of 0.80%)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Ki‐67 positivity (cutoff value of 10.25%)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: MUM1 positivity in FL2000 cohort
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: MUM1 positivity in multivariate Cox regression model for FL2000 cohort
Number of subjects: 572
Study: 21399488

Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin, and continuous infusion of 5‐fluorouracil (ECF)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 85
Study: 19417195

Group type: EXPERIMENTAL
Intervention: VT/VF any time
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Early VT/VF (before the end of cardiac catheterization)
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Late VT/VF (after the end of cardiac catheterization)
Number of subjects: 5745

Group type: COMPARATOR
Intervention: No VT/VF
Number of subjects: 5745
Study: 17244772

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg
Number of subjects: 31
Study: 15642685

Group type: EXPERIMENTAL
Intervention: Low dose oral vitamin K
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11997407

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Total power, HF, LF, and VLF
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: LF:HF ratios and catecholamines
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Treatment effects on HRV
Number of subjects: 641
Study: 9931787

Group type: EXPERIMENTAL
Intervention: Node-excision to lobectomy
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Extensive nerve mobilization
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Non-identification of the nerve
Number of subjects: 1143
Study: 7712526

Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) 18 g administered intravenously for 3 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no CP)
Number of subjects: 50
Study: 2655543

Group type: EXPERIMENTAL
Intervention: Deflazacort (18 + 18 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prednisone (15 + 15 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betamethasone disodium phosphate (1.5 + 1.5 mg)
Number of subjects: 6
Study: 31493952

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (1 mg lidocaine/kg bolus followed by 180 mg lidocaine/hour for 7 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study: 30816665

Group type: EXPERIMENTAL
Intervention: Diabetic kidney disease (DKD) patients
Number of subjects: 60
Study: 26966012

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25425259

Group type: EXPERIMENTAL
Intervention: Mental fatigue (induced by 90 min of the computer‐based Continuous Performance Task AX version)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (90 min of watching emotionally neutral documentaries)
Number of subjects: 12
Study: 24476474

Group type: EXPERIMENTAL
Intervention: EAA (essential amino acids with leucine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: EAA‐Leu (essential amino acids without leucine)
Number of subjects: 8
Study: 21948229

Group type: EXPERIMENTAL
Intervention: Enhanced Study Form (ESF)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Generic Study Form (GSF)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Standard Form
Number of subjects: 317
Study: 19243324

Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia delivery system (CLADS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Manual control of propofol delivery
Number of subjects: 44
Study: 17530108

Group type: EXPERIMENTAL
Intervention: Bupivacaine with meperidine (Group M)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Bupivacaine with fentanyl (Group F)
Number of subjects: 67
Study: 15450787

Group type: EXPERIMENTAL
Intervention: High-activity allele loading of catechol-O-methyltransferase genotype
Number of subjects: 543

Group type: COMPARATOR
Intervention: Catechol-O-methyltransferase valine158 methionine genotypes
Number of subjects: 543
Study: 11589975

Group type: EXPERIMENTAL
Intervention: Cortisporin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 100
Study: 9713782

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 68
Study: 7977713

Group type: EXPERIMENTAL
Intervention: ouabain (0.5 mg i.v. 42 and 18 h before study)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2732784

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day)
Number of subjects: 19
Study: 1096800

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ampicillin (susceptible organisms)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ampicillin (resistant organisms)
Number of subjects: 154
Study: 31819947

Group type: EXPERIMENTAL
Intervention: Implementation intention provision
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (reading a goal intention)
Number of subjects: 32
Study: 30942012

Group type: EXPERIMENTAL
Intervention: Rapid massage at Shuidao (ST 28)
Number of subjects: 200
Study: 27566723

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (3.6mg mean dose at last visit)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 26130740

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study: 23623280

Group type: EXPERIMENTAL
Intervention: CRT plus cetuximab (400 mg/m² on day 1 followed by 250 mg/m² weekly)
Number of subjects: 258

Group type: COMPARATOR
Intervention: CRT only (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² twice daily for four cycles)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: CRT plus cetuximab
Number of subjects: 258

Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 258
Study: 21502556

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18802999

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg/8 hp. o)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16274912

Group type: EXPERIMENTAL
Intervention: Digital-CranioCorpoGraphy (dCCG)
Number of subjects: 33
Study: 11912281

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel (two doses of 0.375 mg each, 12 hours apart)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 10099942

Group type: COMPARATOR
Intervention: Iron alone
Number of subjects: 216

Group type: COMPARATOR
Intervention: Iron and vitamin A
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Iron, vitamin A and zinc
Number of subjects: 216
Study: 7570929

Group type: EXPERIMENTAL
Intervention: WBC-reduced whole blood
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unfiltered whole blood
Number of subjects: 197

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 197
Study: 2189448

Group type: EXPERIMENTAL
Intervention: EEG monitoring with fentanyl 25 to 50 micrograms/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: No EEG monitoring with fentanyl 50 micrograms/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 32

Group type: COMPARATOR
Intervention: No EEG monitoring
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 271593

Group type: EXPERIMENTAL
Intervention: Multi-tufted brush
Number of subjects: 20

Group type: COMPARATOR
Intervention: Space-tufted brush
Number of subjects: 20
Study: 29414244

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 0
Study: 27402145

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 125
Study: 24078055

Group type: EXPERIMENTAL
Intervention: 3-T breast MRI
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 3-T breast MRI in addition to conventional imaging
Number of subjects: 123
Study: 22623617

Group type: EXPERIMENTAL
Intervention: Educational interventions for hand hygiene
Number of subjects: 16

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 16
Study: 20833596

Group type: EXPERIMENTAL
Intervention: Healthy Girls Project intervention (4 weekly workshops with psychoeducational and behavioral components)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study: 18801028

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg daily for 4 months)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 15933496

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Phonophoresis
Number of subjects: 31
Study: 12957702

Group type: EXPERIMENTAL
Intervention: Cognitive remediation exercises
Number of subjects: 54

Group type: COMPARATOR
Intervention: No cognitive intervention (control group)
Number of subjects: 54
Study: 11116772

Group type: EXPERIMENTAL
Intervention: Patient-held shared care records
Number of subjects: 90
Study: 9189040

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) 0.4 gm/kg daily for either 3 days (n = 23) or 5 days (n = 23)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) 3 sessions
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 87
Study: 1443736

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA), n = 31
Number of subjects: 64

Group type: COMPARATOR
Intervention: Face mask (control), n = 33
Number of subjects: 64

Group type: COMPARATOR
Intervention: Face mask (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) and Face mask (control)
Number of subjects: 64
Study: 4022702

Group type: EXPERIMENTAL
Intervention: Soy-based, lactose-free formula (group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard therapy (limited starvation, group B)
Number of subjects: 87
Study: 29087781

Group type: EXPERIMENTAL
Intervention: VARIVAX™ New Seed Process (VARNSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently licensed VAR
Number of subjects: 0
Study: 26769758

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: HHFNC
Number of subjects: 20
Study: 24782199

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron 32 mg IV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg IV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22691456

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (DB group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction with bioabsorbable screw fixation (SBB group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction with metallic screw fixation (SBM group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (SBB group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (SBM group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 20039806

Group type: EXPERIMENTAL
Intervention: DeltaNS1‐H1N1 A/New Caledonia vaccine at 1 of 5 dose levels (6.4, 6.7, 7.0, 7.4, and 7.7 log(10) median tissue culture infective dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DeltaNS1‐H1N1 A/New Caledonia vaccine
Number of subjects: 48
Study: 18949297

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with distilled water (G1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with polyethylene glycol (G2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with polyethylene glycol + CMCP (G3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with glycerin (G4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control (intact crowns)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control (instrumented teeth without temporary dressing)
Number of subjects: 40
Study: 15916468

Group type: EXPERIMENTAL
Intervention: Betaine (6 g/d for 6 weeks)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (approximately 2.6 g/d of choline for 2 weeks)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 12456225

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 461

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 461
Study: 10553160

Group type: EXPERIMENTAL
Intervention: Fludarabine alone (25 mg/m²/day for 5 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fludarabine and idarubicin (FLU-ID: fludarabine 25 mg/m² i.v. on days 1 to 3 and idarubicin 12 mg/m² i.v. on day 1)
Number of subjects: 29
Study: 8635933

Group type: EXPERIMENTAL
Intervention: Prostate cancer volume (VCa)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Volume fraction of the gland involved by carcinoma (VCafx)
Number of subjects: 227

Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 227

Group type: COMPARATOR
Intervention: Cancer-specific PSA
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Calculated tumor volumes of < or = 0.5 cm3, 0.5-4.0 cm3, and > 4.0 cm3
Number of subjects: 227
Study: 1733432

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy with 2 Gy per fraction over 7 weeks)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy in high-risk patients
Number of subjects: 468
Study: 6368889

Group type: EXPERIMENTAL
Intervention: Rifampin-20 (20 mg/kg/dose for four days)
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Rifampin-10 (10 mg/kg/dose for two to four days)
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Rifampin-20 or Rifampin-10
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Rifampin-treated contacts
Number of subjects: 1877
Study: 31730458

Group type: EXPERIMENTAL
Intervention: CCR5 32 allele carriers
Number of subjects: 400
Study: 29517695

Group type: EXPERIMENTAL
Intervention: Group I (n=27; combined ED95 rocuronium and ED95 cisatracurium)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Group S (n=27; dose reduced by 10% of each ED95)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Group L (n=27; dose reduced by 20% of each ED95)
Number of subjects: 81
Study: 26581819

Group type: EXPERIMENTAL
Intervention: Extended medication (26 weeks of nicotine patch + nicotine gum)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Extended medication (8 weeks of nicotine patch + nicotine gum)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Maintenance (phone) counseling
Number of subjects: 544

Group type: COMPARATOR
Intervention: No maintenance counseling
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Medication adherence counseling
Number of subjects: 544

Group type: COMPARATOR
Intervention: No medication adherence counseling
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Automated (medication) adherence calls
Number of subjects: 544

Group type: COMPARATOR
Intervention: No automated adherence calls
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Electronic medication monitoring with feedback and counseling
Number of subjects: 544

Group type: COMPARATOR
Intervention: Electronic medication monitoring alone
Number of subjects: 544
Study: 23787544

Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 μg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 μg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21558570

Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (500 mg of quercetin-3-glucoside, consumed twice a day, totaling 1,000 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: 6% carbohydrate commercial sports drink
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quercetin supplementation
Number of subjects: 15
Study: 19433274

Group type: EXPERIMENTAL
Intervention: Clonidine (0.05 mg, twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levetiracetam (10 mg/kg/day, divided twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 12
Study: 16430539

Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: COMPARATOR
Intervention: N2O with 5% sevoflurane
Number of subjects: 84
Study: 15577771

Group type: EXPERIMENTAL
Intervention: Bilateral ventilation tube insertion and adenoidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (otherwise healthy children)
Number of subjects: 0
Study: 11396392

Group type: EXPERIMENTAL
Intervention: ChromaGen contact lenses
Number of subjects: 14
Study: 9268178

Group type: EXPERIMENTAL
Intervention: Heparinase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Protamine sulfate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 48
Study: 8491998

Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter > 3 mm
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter 2-3 mm
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Coronary segments with diameter < 2 mm
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Proximal coronary segments
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Mid coronary segments
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Distal coronary segments
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Distal segments < 2 mm
Number of subjects: 348
Study: 3301456

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study: 29648858

Group type: EXPERIMENTAL
Intervention: Alliance-focused training (AFT)
Number of subjects: 40
Study: 27029450

Group type: EXPERIMENTAL
Intervention: Noophen 500 mg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Betahistin
Number of subjects: 58
Study: 24493231

Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole (AB) for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antibacterial photodynamic therapy (aPDT) with two episodes
Number of subjects: 36
Study: 22331154

Group type: EXPERIMENTAL
Intervention: Modified supervised toothbrushing program (professional cross-brushing five times per year)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Conventional supervised toothbrushing program (oral health education and dental plaque dying followed by toothbrushing with fluoride dentifrice four times per year)
Number of subjects: 284
Study: 21384736

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Local corticosteroid injection plus splinting
Number of subjects: 34
Study: 18834243

Group type: EXPERIMENTAL
Intervention: OFD with calcium sulfate graft and membrane (CS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OFD with collagen membrane (CM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 51
Study: 21178933

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg-1 bm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15781016

Group type: EXPERIMENTAL
Intervention: cilostazol (group 1, n = 344)
Number of subjects: 689

Group type: COMPARATOR
Intervention: clopidogrel (group 2, n = 345)
Number of subjects: 689